Interestingly, treatment with bevacizumab influences ET-1 plasma level63,64 and is of greater benefit for those ovarian cancer patients with the mesenchymal subtype65 in which ETAR and ZEB1 are overexpressed. This evidence concerns the gene ZEB1 and ovarian carcinoma.